mdxhealth.com (MDXH) Company Sales

Increasing demand for ConfirmMDx tests in urology is driving current revenue, as evidenced by the sales levels of MDxHealth SA (MDXH). The latest figure remains around 0.11. While high scientific and technical potential in oncology DNA marker analysis is underpinned by R&D investments, aggressive competition for insurance contracts with large-scale laboratories is exerting significant pressure on the business's financial results.

mdxhealth.com - MDXH Company Sales (period 07/04/2022 - 11/14/2026)

Comprehensive metric breakdowns and analytics for MDxHealth (MDXH)

- market value and analyst target forecast:

Market Chart MDxHealth, Inc.|MDXH - Price Target Chart

- market capitalization details:

Market Valuation MDxHealth|MDXH - Enterprise Value

- balance sheet equity data:

Equity per Share MDxHealth SA|MDXH - Company Net Assets|Capitalization to Book Value Ratio mdxhealth.com|MDXH - Company Total Assets

- debt and solvency information:

- financial results and valuation multiples details:

MDXH - Net Profit|Expected Net Income MDxHealth SA|MDXH - Price to Earnings Ratio|Future Price to Earnings Multiple mdxhealth.com|MDXH - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio MDxHealth|MDXH - Operating profit EBITDA|Net earnings per share (EPS TTM) MDxHealth SA|MDXH - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months mdxhealth.com|MDXH - Earnings growth in current year|Projected earnings per share growth rate for next year MDxHealth SA

- issuer revenue and sales details:

MDXH - Company Sales|Company Revenue Forecast MDxHealth, Inc.|MDXH - P/S Multiple|Forward Price to Sales MDxHealth

Summary company analysis:MDXH, MDxHealth, Inc.

Investors are verifying the reliability of MDxHealth SA (MDXH) through an analysis of revenue dynamics and estimated multiples. The company's sales performance reflects the daily volume of proceeds from the sale of molecular tests. This metric measures real cash flow, capturing the phases of the economic cycle. Growth in this indicator confirms the efficiency of centralized test processing, which reduces unit costs. The positive trend on the chart demonstrates the scalability of the biopharmaceutical business.

Analysis of competing companies